Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
Daiichi Sankyo
Farmers Insurance
Moodys
Cipla
Mallinckrodt
AstraZeneca
US Army

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANGRELOR

« Back to Dashboard

Clinical Trials for Cangrelor

Trial ID Title Status Sponsor Phase Summary
NCT00102674 Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor Completed The Medicines Company Phase 1 The purposes of this study are to: - Evaluate the tolerability of two cangrelor regimens. - Compare the PD of cangrelor regimens with oral clopidogrel.
NCT00305162 A Clinical Trial to Demonstrate the Efficacy of Cangrelor Terminated The Medicines Company Phase 3 The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
NCT00385138 Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Terminated The Medicines Company Phase 3 The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR).
NCT00699504 Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers Completed The Medicines Company Phase 1 To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cangrelor

Condition Name

Condition Name for Cangrelor
Intervention Trials
Coronary Artery Disease 5
Acute Coronary Syndrome (ACS) 3
STEMI 2
Acute Coronary Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cangrelor
Intervention Trials
Myocardial Infarction 7
Acute Coronary Syndrome 7
Infarction 6
Myocardial Ischemia 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cangrelor

Trials by Country

Trials by Country for Cangrelor
Location Trials
United States 12
Czechia 2
United Kingdom 1
Switzerland 1
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cangrelor
Location Trials
Vermont 3
Florida 2
South Carolina 1
New York 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cangrelor

Clinical Trial Phase

Clinical Trial Phase for Cangrelor
Clinical Trial Phase Trials
Phase 4 7
Phase 3 3
Phase 2 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cangrelor
Clinical Trial Phase Trials
Completed 9
Not yet recruiting 6
Recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cangrelor

Sponsor Name

Sponsor Name for Cangrelor
Sponsor Trials
The Medicines Company 11
University of Florida 2
The Royal Wolverhampton Hospitals NHS Trust 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cangrelor
Sponsor Trials
Other 16
Industry 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Medtronic
Julphar
Merck
McKesson
Cipla
Chubb
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.